Summary: Natus Medical has submitted an FDA 510(k) notification for its point-of-care EEG device, designed to quickly identify seizures in acute care settings. The system uses Natus’ NeuroWorks platform, AI-powered algorithms, and offers remote neurologist collaboration for improved treatment decisions.

Key Takeaways:

  • The point-of-care EEG system aims to enhance seizure detection in ER and ICU environments.
  • Natus’ collaboration with Persyst integrates AI-powered seizure detection algorithms for precision care.

Natus Medical Incorporated has submitted an FDA 510(k) premarket notification to the U.S. FDA for its Natus point-of-care EEG device.

Rapid-Deploy Decision-Support Tool for Seizure Detection

The rapid deploy decision-support tool is designed to quickly help identify non-convulsive seizures (NCSs) and status epilepticus in acute care environments, supporting rapid intervention and streamlining treatment decisions to improve patient outcomes.

This point-of-care EEG system uses the NeuroWorks software platform, enabling remote neurologist collaboration via web browser and incorporating a cybersecurity-certified cloud platform for data security.

AI-Powered Seizure Detection with Persyst

Natus has partnered with Persyst, a developer of spike and seizure detection, to incorporate AI-powered seizure detection algorithms, also under review for FDA 510(k) clearance.

According to Natus, early feedback promotes an easy-to-use system that can be deployed in minutes by ER and ICU staff without the need for an EEG technologist and with clinical information exceeding the expectations of neurologists.

The company expects its point-of-care EEG to deliver the confidence and precision care providers need to support making informed, life-saving decisions in the emergency department and ICU.